Doxapram - CAS 309-29-5
Catalog number: 309-29-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C24H30N2O2
Molecular Weight:
378.52
COA:
Inquire
Targets:
Potassium Channel
Description:
Doxapram is a respiratory stimulant. Administered intravenously, doxapram stimulates an increase in tidal volume, and respiratory rate. Doxapram stimulates chemoreceptors in the carotid bodies of the carotid arteries, which in turn, stimulates the respiratory centre in the brain stem.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Related CAS:
7081-53-0 (HCl)
Appearance:
White to off-white crystalline powder.
Synonyms:
1-ethyl-4- (2-morpholin-4-ylethyl)- 3,3-diphenyl-pyrrolidin-2-one; AHR-619; AHR 619; AHR619; Doxapram; Doxapram hydrochloride, Brand name Dopram, Stimulex or Respiram
Solubility:
Soluble in DMSO, not in water
Storage:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years if stored properly
InChIKey:
XFDJYSQDBULQSI-UHFFFAOYSA-N
InChI:
1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
Canonical SMILES:
O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4
1.Observational Study on Less Invasive Surfactant Administration (LISA) in Preterm Infants<29 Weeks - Short and Long-term Outcomes.
Teig N1, Weitkämper A1, Rothermel J1, Bigge N1, Lilienthal E1, Rossler L1, Hamelmann E1. Z Geburtshilfe Neonatol. 2015 Dec;219(6):266-273. Epub 2015 Nov 9.
Background: A recent trial has demonstrated short-term benefits of a new minimal invasive procedure of surfactant administration in spontaneously breathing preterm infants ≥26 weeks (less invasive surfactant administration, LISA). Aim: To assess safety as well as short- and long-term outcomes of the LISA procedure in preterm infants between 23-28 weeks of gestation. Study design: Preterm infants born between 23+0 and 28+6 weeks gestational age during 2 periods, 18 months before (Period 1, n=44) and 18 months after introduction of LISA (Period 2, n=53), were analyzed for neonatal outcomes. 52% of discharged infants were assessed for neurodevelopmental outcome at corrected age of 3 years. Results: In Period 2, 66% of the preterm infants needing surfactant were treated by the new method of LISA. In this period, fewer patient had to be ventilated during the first 3 days of life (42 vs. 77%, p<0.0005) and overall (55 vs. 77%, p=0.02). The median duration of mechanical ventilation was 2 vs.
2.Reversal of morphine-induced respiratory depression by doxapram in anesthetized rats.
Haji A1, Kimura S2, Ohi Y2. Eur J Pharmacol. 2016 Mar 30. pii: S0014-2999(16)30192-3. doi: 10.1016/j.ejphar.2016.03.053. [Epub ahead of print]
The present study was undertaken to investigate whether doxapram, a blocker of tandem pore K+ (TASK-1/-3) channels, is a useful tool for recovery from morphine-induced ventilatory disturbances. Spontaneous ventilation and the hind leg withdrawal response against noxious thermal stimulation were recorded simultaneously in anesthetized rats. Morphine (1.0mg/kg, i.v.) decreased the minute volume resulting from depression of the ventilatory rate and tracheal airflow. Concomitantly, it prolonged the latency of withdrawal response against the thermal stimulation. Subsequent intravenous injection of doxapram recovered the morphine-induced ventilatory depression. This effect of doxapram declined rapidly after a single injection (1.0-3.0mg/kg, i.v.) but persisted with a continuous infusion (0.33mg/kg/min). Neither single injection nor continuous infusion of doxapram had any detectable effect on the analgesic potency of morphine. The central respiratory activity was recorded from the phrenic nerve in anesthetized, vagotomized, paralyzed and artificially ventilated rats.
3.Breathing Stimulant Compounds Inhibit TASK-3 Potassium Channel Function Likely by Binding at a Common Site in the Channel Pore.
Chokshi RH1, Larsen AT1, Bhayana B1, Cotten JF2. Mol Pharmacol. 2015 Nov;88(5):926-34. doi: 10.1124/mol.115.100107. Epub 2015 Aug 12.
Compounds PKTHPP (1-{1-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidin-4-yl]piperidin-4-yl}propan-1-one), A1899 (2''-[(4-methoxybenzoylamino)methyl]biphenyl-2-carboxylic acid 2,4-difluorobenzylamide), and doxapram inhibit TASK-1 (KCNK3) and TASK-3 (KCNK9) tandem pore (K2P) potassium channel function and stimulate breathing. To better understand the molecular mechanism(s) of action of these drugs, we undertook studies to identify amino acid residues in the TASK-3 protein that mediate this inhibition. Guided by homology modeling and molecular docking, we hypothesized that PKTHPP and A1899 bind in the TASK-3 intracellular pore. To test our hypothesis, we mutated each residue in or near the predicted PKTHPP and A1899 binding site (residues 118-128 and 228-248), individually, to a negatively charged aspartate. We quantified each mutation's effect on TASK-3 potassium channel concentration response to PKTHPP. Studies were conducted on TASK-3 transiently expressed in Fischer rat thyroid epithelial monolayers; channel function was measured in an Ussing chamber.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Potassium Channel Products


CAS 149908-53-2 Azimilide

Azimilide
(CAS: 149908-53-2)

Azimilide, also called as Stedicor, a chlorophentlturany compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels. Phase III

CAS 1951-25-3 Amiodarone

Amiodarone
(CAS: 1951-25-3)

Amiodarone, an iodine-rich benzofuran derivative, as a vaughan-Williams Class III antiarrhythmic agent it is an ATP-sensitive potassium channel inhibitor (IC50=...

CAS 332378-43-5 S 9947

S 9947
(CAS: 332378-43-5)

S 9947 is a Kv1.5 or IKur channel blocker exhibiting a dual inhibitory effect against cloned (Kv1.5) and native (IKur) cardiac potassium current.

NS6180
(CAS: 353262-04-1)

NS6180 is a potent KCa3.1 channel blocker (IC50 values are 9, 14 and 15 nM for rat, human and mouse erythrocyte KCa3.1 channels respectively). NS6180 prevents T...

CAS 18711-16-5 NS309

NS309
(CAS: 18711-16-5)

NS309 is a small- and intermediate- conductance Ca2+-activated K+ channels of SK and IK types whereas exhibits no activity at BK channels.

PF-05020182
(CAS: 1354712-92-7)

PF05020182 is novel potent and selective Kv7.2/4 potassium channel opener originated by Pfizer. It can inhibit convulsions in the MES assay at doses tested, con...

CAS 7081-53-0 Doxapram HCl

Doxapram HCl
(CAS: 7081-53-0)

Doxapram HCl inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.

CAS 928774-43-0 PF-3716556

PF-3716556
(CAS: 928774-43-0)

PF 3716556 is a potent and selective P-CAB with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, r...

CAS 748810-28-8 Vernakalant hydrochloride

Vernakalant hydrochloride
(CAS: 748810-28-8)

Vernakalant hydrochloride, also known as RSD1235, is a novel, relatively atrial-selective antiarrhythmic drug which can terminate acute atrial fibrillation (AF)...

CAS 364-98-7 Diazoxide

Diazoxide
(CAS: 364-98-7)

Diazoxide is a benzothiadiazine derivative which acts as a potassium channel activator.

GYKI-16638
(CAS: 778564-77-5)

GYKI-16638 is Potassium channel and Sodium channel antagonist originated by Nonindustrial source. It is a novel antiarrhythmic agent.

CAS 207844-01-7 Mitiglinide calcium hydrate

Mitiglinide calcium hydrate
(CAS: 207844-01-7)

Mitiglinide calcium hydrate, a derivative of benzylsuccinic acid, is a highly selective KATP channel antagonist.

CAS 29094-61-9 Glipizide

Glipizide
(CAS: 29094-61-9)

Glipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. Glipizide is used to treat high blood sugar levels caused by a type...

CAS 522-51-0 Dequalinium Chloride

Dequalinium Chloride
(CAS: 522-51-0)

Dequalinium Chloride is a PKC inhibitor with IC50 of 7-18 μM, and also a selective blocker of apamin-sensitive K+ channels with IC50 of 1.1 μM.

CAS 21187-98-4 Gliclazide

Gliclazide
(CAS: 21187-98-4)

Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM.

CAS 184653-84-7 Carabersat

Carabersat
(CAS: 184653-84-7)

Carabersat, also called as SB 204269, an orally-effective anticonvulsant agent, is an ATP-sensitive potassium channel (K-ATP) opener with potential effect to t...

AZD1305
(CAS: 872045-91-5)

AZD1305 is a potassium channel and sodium channel antagonist. It can inhibit rapidly the activating delayed-rectifier potassium current, L-type calcium current,...

RPR-260243
(CAS: 668463-35-2)

RPR-260243 is a selective activator of the Human Ether-ago-go-Related Gene (hERG) (IC50 = 58 nM).

BMS-919373
(CAS: 1272353-82-8)

This active molecular is a Kv1.5 potassium channel inhibitor originated by Bristol-Myers Squibb. Treatment for paroxysmal atrial fibrillation is in Phase II cli...

AVE 0118 hydrochloride

AVE 0118 hydrochloride is a potassium channel blocker that has the potential for the treatment of sleep apnea syndrome. AVE 0118 functions without apparent effe...

Chemical Structure

CAS 309-29-5 Doxapram

Quick Inquiry

Verification code

Featured Items